

**Fingolimod Dr.Reddys 0.5mg hard capsules**

**Fingolimod**

**PREGNANCY-SPECIFIC**

**Patient Reminder Card**

Approved by Malta Medicine Authority –  
October 2024

### **Before starting fingolimod treatment**

**Fingolimod is contraindicated in pregnant women and women of child-bearing potential (including adolescents) not using effective contraception.**

At treatment start and then regularly, your doctor will inform you about the teratogenic risk (causes defects to unborn babies) and required actions to minimise this risk.

A pregnancy test must be conducted and the negative result verified by a doctor before starting treatment.

Your doctor will inform you about the need for effective contraception while on treatment and for 2 months after discontinuation. Talk to your doctor about the most effective contraception options available to you.

Please read the fingolimod patient guide leaflet provided by your doctor.

### **While you are taking fingolimod**

While on treatment women must not become pregnant.

Patients must use effective contraception while taking fingolimod.

Women must not become pregnant during treatment and for 2 months after discontinuing treatment.

Pregnancy tests must be repeated at suitable intervals.

Your doctor will provide regular counselling about fingolimod's serious risk to the foetus.

If you become pregnant or if you want to become pregnant please discuss this with your doctor because fingolimod treatment must be discontinued.

In the event of a pregnancy your doctor will provide counselling.

Your doctor will give you medical advice regarding the harmful effects of fingolimod to the foetus and will provide an evaluation of the potential outcome.

### **After stopping fingolimod treatment**

Inform your doctor immediately if you believe your MS is getting worse (e.g. weakness or visual changes) or if you notice any new symptoms after stopping treatment with fingolimod due to pregnancy.

Effective contraception is needed for 2 months after stopping fingolimod treatment because of the length of time it takes for fingolimod to leave the body.

### **Reporting of side effects**

Please report suspected adverse drug reactions (ADRs) to Malta Medicine Authority via the ADR Reporting Website:  
[www.medicinesauthority.gov.mt/adrportal](http://www.medicinesauthority.gov.mt/adrportal)

Alternatively, you can report a suspected side effect to EJ Busuttil Ltd by calling 2147184. This service is available 24/7.

When reporting please provide as much information as possible. By reporting side effects, you can help provide more information on the safety of this medicine.

Adverse events should also be reported to [safety@ejbusuttil.com](mailto:safety@ejbusuttil.com)

For further information please contact EJ Busuttil Ltd via email to [medicines@ejbusuttil.com](mailto:medicines@ejbusuttil.com) or by phoning on 21447184

Date of preparation: October 2024

Version 01

Approved by Malta Medicines  
Authority – October 2024